Scarica l'app Stockscreener
24.12
2.42%
0.57
Arcus Biosciences Inc Borsa (RCUS) Ultime notizie
Arcus Biosciences (RCUS) director receives 5,700 RSUs and 16,900 stock options - Stock Titan
Arcus Biosciences (RCUS) grants director RSUs and stock options - Stock Titan
Arcus Biosciences (RCUS) director receives RSU and stock option awards - Stock Titan
Arcus Biosciences counsel exercises 34,090 options | RCUS Insider Trading - Stock Titan
Director David L. Lacey receives RCUS stock awards at Arcus Biosciences (RCUS) - Stock Titan
[Form 4] Arcus Biosciences, Inc. Insider Trading Activity - Stock Titan
Arcus Biosciences (RCUS) director Antoni Ribas receives RSU and option awards - Stock Titan
Arcus Biosciences (RCUS) director receives new RSU and stock option grants - Stock Titan
Arcus Biosciences (NYSE: RCUS) reports 2026 shareholder vote results - Stock Titan
Arcus Biosciences Jumps 6.9% Amid Sector-Wide Rally - AlphaStreet
Arcus Biosciences Inc Annual Shareholders Meeting Transcript - GuruFocus
Arcus Biosciences, Inc. (RCUS) reports Q1 loss, beats revenue estimates - MSN
Arcus Biosciences Drops 7.0% After LifeSci Capital Initiates at Outperform - AlphaStreet
What Did Arcus Biosciences Highlight at the Goldman Sachs Healthcare Conference - Kavout
New hire at Arcus Biosciences gets stock options and RSUs - Stock Titan
Arcus Biosciences, Inc. (RCUS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026Slideshow (NYSE:RCUS) 2026-06-09 - Seeking Alpha
Arcus Biosciences Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Arcus, Bristol Myers team up to advance kidney cancer study - MSN
Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $36.73, Implies 58% Upside - TradingView
LifeSci Capital Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $46 - Moomoo
(RCUS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
A Look At Arcus Biosciences (RCUS) Valuation After Recent Share Price Weakness - Sahm
Is Arcus‑BMS Kidney Cancer Collaboration Altering The Investment Case For Arcus Biosciences (RCUS)? - Sahm
Arcus Biosciences (RCUS) Earnings Date and Reports 2026 - MarketBeat
Arcus Biosciences Jumps 5.7% Amid Sector-Wide Rally - AlphaStreet
RCUS Initiated Coverage by LifeSci Capital -- Rating Set to Outp - GuruFocus
Lifesci Capital Initiates Coverage on Arcus Biosciences (NYSE:RCUS) - MarketBeat
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study - Yahoo Finance
Truist Financial Maintains Arcus Biosciences(RCUS.US) With Buy Rating - Moomoo
With billions of dollars at stake, trio of Bay Area biotechs nail down deals - The Business Journals
BMY Collaborates with Arcus Biosciences on Clinical Trial for Ca - GuruFocus
Arcus Biosciences Partners With Bristol Myers Squibb to Develop Kidney Cancer Treatment - marketscreener.com
Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial - marketscreener.com
New drug combo from Arcus and BMS targets advanced kidney cancer - Stock Titan
Arcus Biosciences Drops 6.0% Amid Sector-Wide Selling - AlphaStreet
Arcus Biosciences chief accounting officer sells $66,023 in stock By Investing.com - Investing.com South Africa
Arcus Biosciences chief accounting officer sells $66,023 in stock - Investing.com
Arcus Biosciences (RCUS) CAO 10b5-1 sale of 2,562 shares - Stock Titan
[144] Arcus Biosciences, Inc. SEC Filing - Stock Titan
Arcus Biosciences (RCUS) Surges 3.6%: Can the Breakout Hold Above Key Resistance?getLinesFromResByArray error: size == 0 - The League of Women Voters of Texas
Biotech Catalysts Put Three Small Caps On Watch - Kalkine Media
RCUS Stock Price, Quote & Chart | ARCUS BIOSCIENCES INC (NYSE:RCUS) - ChartMill
Arcus Biosciences joins Goldman Sachs chat, offers live webcast June 9 - Stock Titan
Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - marketscreener.com
Liquidity Mapping Around (RCUS) Price Events - Stock Traders Daily
Arcus halts Gilead-partnered late-stage trial for lung cancer drug - MSN
Arcus Biosciences (RCUS) Insider Trading Activity 2026 - MarketBeat
Truist Financial Initiates Arcus Biosciences(RCUS.US) With Buy Rating, Announces Target Price $35 - Moomoo
RCUS Assumes Buy by Truist Securities -- Price Target Raised to $35 - GuruFocus
Arcus Biosciences Coverage Assumed by Truist Securities at Buy - Moomoo
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):